Anzeige
Mehr »
Dienstag, 17.06.2025 - Börsentäglich über 12.000 News
Von SOL zu BTC: Pioneer aktiviert automatisierte Bitcoin-Treasury über Kora AI Beta
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Realtimekurse aktiv

WKN: A2DV3C | ISIN: US92536C1036 | Ticker-Symbol: FMW
Tradegate
16.06.25 | 15:15
0,521 Euro
+0,48 % +0,003
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VERU INC Chart 1 Jahr
5-Tage-Chart
VERU INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,5100,53016.06.
0,5010,53516.06.

Aktuelle News zur VERU Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiVeru Inc.: Veru to Participate in the Virtual BTIG Obesity Health Forum7
30.05.Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave13
30.05.Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vitals Farms to leave37
28.05.Muscle-sparing obesity drug safe for Phase 3 trial, Veru says30
28.05.Veru's Enobosarm Shows Muscle In Wegovy Combo Trial53
28.05.Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ...171--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial...
► Artikel lesen
08.05.Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial35
VERU Aktie jetzt für 0€ handeln
08.05.VERU INC. - 10-Q, Quarterly Report1
08.05.JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level414Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN...
► Artikel lesen
08.05.Veru Inc.: Veru Participates in a Virtual Investor KOL Connect Segment6
08.05.VERU INC. - 8-K, Current Report3
08.05.Veru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress549--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second...
► Artikel lesen
07.05.A Peek at Veru's Future Earnings7
07.05.Veru Q2 2025 Earnings Preview4
01.05.Veru Inc.: Veru to Report Fiscal 2025 Second Quarter Financial Results on May 88
16.04.Veru Inc.: Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit12
14.03.VERU INC. - 8-K, Current Report13
13.02.Veru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatment49
13.02.VERU INC. - 10-Q, Quarterly Report4
13.02.Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress541--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater...
► Artikel lesen
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen